Metabolic, toxicological, and safety considerations for drugs used to treat ADHD

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 5, 2012, Pages 543-552

  Duong, Sophie ^a   Chung, Kara ^a   Wigal, Sharon B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ADHD; medication; metabolism; non stimulants; pharmacotherapy; stimulants

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CLONIDINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; FLUOXETINE; GUANFACINE; LISDEXAMFETAMINE; METHYLPHENIDATE; PAROXETINE; PLACEBO; QUINIDINE;

ABDOMINAL PAIN; AGITATION; ANOREXIA; ANXIETY; APPETITE; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; BRADYCARDIA; CHILDHOOD DISEASE; COMORBIDITY; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PLASMA CONCENTRATION-TIME CURVE; REVIEW; SEDATION; SIDE EFFECT; SKIN IRRITATION; SOMNOLENCE; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VASOCONSTRICTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS AS TOPIC; CLONIDINE; COMORBIDITY; DRUG COMBINATIONS; DRUG TOXICITY; GUANFACINE; HUMANS; METHYLPHENIDATE; PROPYLAMINES;

EID: 84859976751     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.671295     Document Type: Review

References (84)

1. Wilens TE, Spencer TJ. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med 2010;122(5):97-109
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Text Revision Am Psychiatry Assoc; Washington, DC: 2000
3. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-8 (Pubitemid 46972911)
4. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry 2006;163:716-23 (Pubitemid 44464584)
5. Fayyad J, De Graaf R, Kessler J, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007;190:402-9 (Pubitemid 46706952)
6. Centers for Disease Control and Prevention. Increasing prevalence of parent-reported attention-deficit/ hyperactivity disorder among children - United States, 2003 and 2007. Morb Mortal Wkly Rep 2010;59(44):1439-43
7. Cylert and generic pemoline products. FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Research, 2005. Available from: http://www.fda.gov/Safety/ MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ ucm151073.htm [Last accessed 10 October 2011]
8. Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009;23(1):21-31
9. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003;13(1):53-63 (Pubitemid 36570188)
10. Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with attentiondeficit/ hyperactivity disorder.. Pediatrics 2011;127(6):doi:10.1542/ peds. 2010-1260
11. Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48:155-65
12. Musshoff F. Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine. Drug Metab Rev 2000;32(1):15-44 (Pubitemid 30123962)
13. Kraemer T, Maurer HH. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit 2002;24:277-89 (Pubitemid 34248035)
14. Adderall medication guide. DSM Pharmaceuticals, Inc., Greenville, NC; 2007
15. Davis JM, Kopin IJ, Lemberge L, et al. Effects of urinary pH on amphetamine metabolism. Drug Metab Man 1971;179(1):493-501
16. Poklis A, Still J, Slattum PW, et al. Urinary excretion of d-amphetamine following oral doses in humans: implications for urine drug testing. J Anal Toxicol 1998;22:481-6 (Pubitemid 28457821)
17. Dexedrine prescribing information. GlaxoSmithKline, Research, Triangle Park, NC; 2001
18. Adderall XR prescribing information. Shire US Inc., Wayne, PA; 2010
19. Steinkellner T, Freissmuth M, Sitte HH, et al. The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine. Biol Chem 2011;392:103-15
20. Greenhill L. Clinical effects of stimulant medication in ADHD. In: Soltnao MV, Arnsten AFT, Castellanos FX, editors. Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. Oxford University; New York: 2001
21. Kolar D, Keller A, Golfinopoulos M, et al. Treatment of adults with attentiondeficit/ hyperactivity disorder. Neuropsychiatr Dis Treat 2008;4(2):389-403 (Pubitemid 351714696)
22. Zhu J, Spencer TJ, Liu-Chen LY, et al. Methylphenidate and ìopioid receptor interactions: a pharmacological target for prevention of stimulant abuse. Neuropharmacology 2011;61:283-92
23. White SR. Amphetamine toxicity. Semin Respir Crit Care Med 2002;23(1):27-34
24. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004;113:762-9
25. Swanson J, Greenhill L, Wigal T. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 2006;45:1304-13 (Pubitemid 44665447)
26. Vyvanse prescribing information. Shire US Inc., Wayne, PA; 2011
27. Wigal SB, Kollins SH, Childress AC, Adeyi B. Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day. Child Adolesc Psychiatr Ment Health 2010;4:32
28. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat 2010;6:317-27
29. Krishnan SM, Pennick M, Stark JG. Metabolism, distribution and elimination of lisdexamfetamine dimesylate. Clin Drug Invest 2008;28(12):745-55
30. Goodman DW. Lisdexamfetamine dimesylate (Vyvanse), a prodrug stimulant for attention-deficit/ hyperactivity disorder. Pharm Ther 2010;35(5):273-87
31. Ermer J, Homolka R, Martin P, et al. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol 2010;50:1001-11
32. Wigal SB, Wigal TL, Kollins SH. Advances in methylphenidate drug delivery systems for ADHD therapy. Advan ADHD. 2006;1:4-7
33. Lyseng-Williamson KA, Keating GM. Extended-release methylphenidate (Ritalin LA). Drugs 2002;62(15):2251-9
34. Sun Z, Murry DJ, Sanghani SP, et al. Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther 2004;310(2):469-76 (Pubitemid 38988889)
35. Ritalin prescribing information. Novartis Pharmaceuticals Corp., East Hanover, NJ; 2007
36. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000;75:711-21 (Pubitemid 30441501)
37. Wigal SB, Gupta S, Greenhill L, et al. Pharmacokinetics of methylphenidate in preschoolers with Attention-Deficit/ Hyperactivity Disorder. J Child Adolesc Psychopharmacol 2007;17:153-64 (Pubitemid 46828911)
38. Methylin . Mallinckrodt, Inc., Hazelwood, MO; 2010
39. Ritalin LA prescribing information. Novartis Pharmaceuticals Corp., East Hanover, NJ; 2007
40. Metadate CD. UCB, Inc., Smyrna, GA; 2007
41. Concerta prescribing information. McNeil Pediatrics, Tutusville, NJ; 2010
42. Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 2003;23(10):1281-99 (Pubitemid 37221923)
43. Focalin XR prescribing information. Novartis Pharmaceuticals Corp., East Hanover, NJ; 2011
44. Markowitz JS, Patrick KS. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmocol 2008;28(3):S54-61
45. Pierce D, Dixon CM, Wigal SB, et al. Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. J Child Adolesc Psychopharmacol 2008;18(4):355-64
46. Daytrana prescribing information. Shire US Inc., Wayne, PA; 2010
47. Bell GH, Novak AJ, Griffin WC, et al. Transdermal and oral dl-methylphenidate-ethanol interactions in C57BL/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrations. J Pharm Sci 2011;100(7):2966-78
48. Heal DJ, Pierce DM. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 2006;20(9):713-38 (Pubitemid 44373701)
49. Pierce D, Katic A, Buckwalter M, et al. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. J Clin Psychopharmocol 2010;30(5):554-64
50. Klein-Schwartz W. Abuse and toxicity of methylphenidate. Curr Opin Pediatr 2002;14:219-23 (Pubitemid 34412168)
51. Pliszka SR, Matthews TL, Braslow KJ, et al. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:520-6
52. Wilens TE, Boellner SW, Lopez FA, et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2008;47(6):700-8
53. Zhu H, Patrick KS, Markowitz JS. Enantiospecific determination of dl-methylphenidate and dl-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: application to human ethanol interactions. J Chromatogr 2011;879:783-8
54. Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009;48(3):240-8
55. Chalon SA, Desager J, DeSante KA, et al. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther 2003;73(3):178-91 (Pubitemid 36269669)
56. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharm 2003;13:53-63 (Pubitemid 36570188)
57. Bertilsson L, Dahl ML, Dalen P, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111-22 (Pubitemid 34264265)
58. Cascorbi I. Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication. Eur J Clin Invest 2003;33(2):17-22
59. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;325:2211-21
60. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit-hyperactivity disorder in children and adolescents. Pediatr Drugs 2009;11(3):203-26
61. Strattera prescribing information. Eli Lilly and Co., Indianapolis, IN; 2003
62. Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008;47(2):209-18 (Pubitemid 351158789)
63. Parker C. Pharmacological treatments for ADHD. Prog in Neurology and Psychiatry. 2009; published online 7 August 2009; doi: 10.1002/pnp.128
64. Wernicke JF, Holdridge KC, Jin L. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol 2007;49:498-502 (Pubitemid 47018494)
65. Kratochvil CJ, Mechelson D, Newcorn JH, et al. High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses. J Am Acad Child Adolesc Psychiatry 2007;46(9):1128-37 (Pubitemid 47295924)
66. Kapvay prescribing information. Shionogi Pharma, Inc., Atlanta, GA; 2010
67. Houston MC. Clonidine hydrochloride: review of pharmacologic and clinical aspects. Prog Cardiovasc Dis 1981;23(5):337-50
68. Larsson P, Nordlinder A, Bergendahl HTG, Lonnqvist P. Oral bioavailability of clonidine in children. Pediatr Anesth 2011;21:335-40
69. Ming X, Mulvey M, Mohanty S, et al. Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders. Adolesc Health Med Ther 2011;2:105-12
70. Vongpatanasin W, Kario K, Atlas SA, et al. Central sympatholytic drugs. J Clin Hypertens 2011;13(9):658-61
71. Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002;58(4):527-36
72. Wilens TE, Spencer TJ. Combining methylphenidate and clonidine. J Am Acad Child Adolesc Psychiatry 1999;38(5):614-16
73. Daviss WB, Patel NC, Robb AS, et al. Clonidine for attention-deficit/ hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008;47(2):189-96
74. Intuniv prescribing information. Shire Pharmaceuticals, Inc., Wayne, PA; 2011
75. Posey DJ, McDougle CJ. Guanfacine and guanfacine extended release: treatment for ADHD and related disorders. CNS Drug Rev 2007;13(4):465-74 (Pubitemid 350233473)
76. Muir VJ, Perry CM. Guanfacine extended-release in attention-deficit hyperactivity disorder. Drugs 2010;70(13):1693-702
77. Strange BC. Once-daily treatment of ADHD with guanfacine: patient implications. Neuropsychiatr Dis Treat 2008;4(3):499-506 (Pubitemid 352037829)
78. Banaschewski T, Roessner V, Dittmann RW, et al. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004;13:102-16
79. Palumbo DR, Sallee FR, Pelham WE, et al. Clonidine for attention-deficit/ hyperactivity disorder: I. efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008;47(2):180-8 (Pubitemid 351158786)
80. Preskorn SH. Polypharmacy: when is it rational? J Pract Psychiatry Behav Health 1995;1:92-8
81. Niculescu AB III, Hulvershorn LA. Toward early, personalized, rational polypharmacy in psychiatry: a tri-dimensional approach. Psychopharmacol Rev 2010;45(2):9-16
82. Sallee FR. The role of alpha2-adrenergic agonists in attention-deficit/ hyperactivity disorder. Postgrad Med 2010;122(5):78-87
83. Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term stimulant medication treatment of attention-deficit/ hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr 2006;27(1):1-10 (Pubitemid 44315107)
84. Hammerness P, Georgiopoulos A, Doyle RL, et al. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol 2009;19(5):493-9